Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Odontogenic Cysts 2 Lung Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Nose Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms 1 Liver Neoplasms 1 Kidney Neoplasms 1 Head and Neck Neoplasms 1 Esthesioneuroblastoma, Olfactory 1 Colonic Neoplasms 1 Carcinoma, Neuroendocrine 1 Breast Neoplasms 1 Anus Neoplasms 1

Interventions

enzalutamide 94 Magnetic Resonance Spectroscopy 85 Specimen Handling 66 Prednisone 63 Androgen Antagonists 59 Abiraterone Acetate 57 apalutamide 55 Radiosurgery 52 darolutamide 48 Radiotherapy 47 Leuprolide 46 abiraterone 45 Docetaxel 42 Pluvicto 32 Biopsy 31 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30 Radiation 30 relugolix 28 Surveys and Questionnaires 28 gallium 68 PSMA-11 26 Standard of Care 26 pembrolizumab 25 Goserelin 25 Triptorelin Pamoate 24 Gonadotropin-Releasing Hormone 23 bicalutamide 22 Brachytherapy 21 Carboplatin 20 cabazitaxel 19 X-Rays 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × Radionuclide Imaging × 1 year × Clear all

NCT06003556 2026-06-03

P-GAP

University of Alberta

Phase 2 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡